ChiCTR2600124275 版本V1.0 版本创建时间2026/05/09 15:22:30 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600124275 

最近更新日期:

Date of Last Refreshed on:

2026-05-09 15:22:11 

注册时间:

Date of Registration:

2026-05-09 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

虚拟现实技术对减轻患儿静脉穿刺疼痛的效果分析

Public title:

Analysis of the Effect of Virtual Reality Technology on Alleviating Venipuncture Pain in Children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

虚拟现实技术对减轻患儿静脉穿刺疼痛的效果分析

Scientific title:

Analysis of the Effect of Virtual Reality Technology on Alleviating Venipuncture Pain in Children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

顾丽香 

研究负责人:

顾丽香 

Applicant:

Gu LiXiang 

Study leader:

Gu LiXiang 

申请注册联系人电话:

Applicant telephone:

+86 133 6825 7068

研究负责人电话:

Study leader's
telephone:

+86 133 6825 7068

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2532740865@qq.com

研究负责人电子邮件:

Study leader's E-mail:

2532740865@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福州市晋安区鼓山镇横屿路966号

研究负责人通讯地址:

福州市晋安区鼓山镇横屿路966号

Applicant address:

No. 966, Hengyu Road, Gushan Town, Jin'an District, Fuzhou City, Fujian Province

Study leader's address:

No. 966, Hengyu Road, Gushan Town, Jin'an District, Fuzhou City, Fujian Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

福建省儿童医院

Applicant's institution:

Fujian Children's Hospital

研究负责人所在单位:

福建省儿童医院

Affiliation of the Leader:

Fujian Children's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026ETKLRK01019

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建省儿童医院伦理委员会

Name of the ethic committee:

Ethics Committee of Fujian Children's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-05 00:00:00

伦理委员会联系人:

林衿

Contact Name of the ethic committee:

Lin Jing

伦理委员会联系地址:

福州市晋安区鼓山镇横屿路966号

Contact Address of the ethic committee:

No. 966, Hengyu Road, Gushan Town, Jin'an District, Fuzhou City, Fujian Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 591 8611 2266

伦理委员会联系人邮箱:

Contact email of the ethic committee:

fjsetyyll@126.com

研究实施负责(组长)单位:

福建省儿童医院

Primary sponsor:

Fujian Children's Hospital

研究实施负责(组长)单位地址:

福州市晋安区鼓山镇横屿路966号

Primary sponsor's address:

No. 966, Hengyu Road, Gushan Town, Jin'an District, Fuzhou City, Fujian Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

福州

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建省儿童医院

具体地址:

福州市晋安区鼓山镇横屿路966号

Institution
hospital:

Fujian Children's Hospital

Address:

No. 966, Hengyu Road, Gushan Town, Jin'an District, Fuzhou City, Fujian Province

经费或物资来源:

福建医科大学启航基金项目(一般)

Source(s) of funding:

Fujian Medical University's Venture Fund Project (General)

研究疾病:

呼吸感染类疾病  

Target disease:

Respiratory infection-related diseases

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在借助科学严谨的分层随机对照试验设计,系统性地探究虚拟现实技术作为一种创新性非药物干预手段,在静脉穿刺操作中对不同年龄段患儿群体疼痛管理的效果,并评估其临床应用潜力与适用性。  

Objectives of Study:

This study aims to systematically investigate the efficacy of virtual reality technology as an innovative non-pharmacological intervention in pain management for pediatric patients of different age groups during venipuncture procedures, and to evaluate its clinical application potential and suitability, through a scientifically rigorous stratified randomized controlled trial design.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄3~18岁;? 2.穿刺前疼痛评分为0分; 3.拟穿刺部位无瘢痕、过敏及静脉血栓的患儿; 4.征得患儿及父母知情同意,签署知情同意书。

Inclusion criteria

1. Age 3–18 years; 2. Pre-puncture pain score of 0; 3. No scars, allergies, or venous thrombosis at the intended puncture site; 4. Informed consent obtained from the child and parents, with signed informed consent form.

排除标准:

1.无法佩戴虚拟眼镜的患儿; 2.凝血功能异常的患儿; 3.穿刺前30 min使用过镇痛剂或镇静剂。

Exclusion criteria:

1. Children unable to wear virtual glasses; 2. Children with coagulation dysfunction; 3. Children who have used analgesics or sedatives within 30 minutes prior to puncture.

研究实施时间:

Study execute time:

From 2022-12-30 00:00:00 To 2026-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-03-10 00:00:00 To 2026-12-30 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

56

Group:

control group

Sample size:

干预措施:

对照组在常规静脉穿刺操作中采取常规护理

干预措施代码:

Intervention:

Conventional nursing care is adopted during routine venipuncture operation

Intervention code:

组别:

试验组

样本量:

56

Group:

experimental group

Sample size:

干预措施:

患儿静脉穿刺应用虚拟现实技术

干预措施代码:

Intervention:

Application of virtual reality technology in pediatric venipuncture

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China

Province:

Fu ZJian

City:

Fu Zhou

单位(医院):

福建省儿童医院 

单位级别:

三甲 

Institution
hospital:

Fujian Children's Hospital

Level of the institution:

Grade A

测量指标:

Outcomes:

指标中文名:

疼痛

指标类型:

主要指标

Outcome:

Pain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

穿刺成功例数

指标类型:

次要指标

Outcome:

Number of successful puncture cases

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件

指标类型:

次要指标

Outcome:

Adverse event

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

满意度

指标类型:

次要指标

Outcome:

Degree of satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 3 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究人员采用随机数字表法,生成随机分配序列,将患儿按1:1比例随机分为试验组与对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers randomly assigned the pediatric patients undergoing venipuncture into a control group and an experimental group using a random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究预计在全部受试者随访完成、项目结题且主要研究成果正式发表后24个月开放数据共享。 共享方式:仅接受医学科研用途的定向书面申请,经项目负责人与本单位伦理委员会双重审核批准后,提供去标识化、脱敏处理后的原始个体数据;不进行全网公开批量发布,全程严格保护未成年人受试者隐私安全。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the completion of all subject follow-up, study closure and publication of primary study outcomes, de-identified individual participant data will be available for reasonable academic research requests within 24 months. Data will be shared only upon formal written application and dual approval by the principal investigator and the Institutional Ethics Committee. No open public online release will be conducted to fully protect the privacy of minor participants.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用统一纸质病例报告表(CRF)采集全部研究数据,双人核对无误后加密存档,全程规范质控,严格保护受试者隐私。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Study data are collected by standard paper CRF, double verified and encrypted archived, with standardized quality control and strict privacy protection.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-05-09 15:22:11